- Standard panels are built to detect disease, not to describe health — a result can sit inside the reference range while trending steadily in the wrong direction.
- In a systematic review of 15 discordance studies covering 593,354 participants, ApoB outperformed LDL cholesterol in 9 of 9 direct comparisons.
- Fasting insulin, hs-CRP, ApoB and Lp(a) change management decisions more often than total cholesterol does.
- A single result is a snapshot; the clinical value comes from trends read alongside symptoms, training, sleep and medication.
- Testing only matters if it ends in a written, prioritised plan and a retest date.
The problem with "everything looks normal"
Most people have had this conversation. You describe fatigue, brain fog, weight that will not move. Blood is drawn, results come back, and you are told everything looks normal. Nothing is technically wrong with that statement — and it is also close to useless. Standard panels were designed as disease-detection tools, and their reference ranges are built from broad populations that include a great many people who are metabolically unwell. Sitting inside that range means you resemble the average adult, not that your physiology is where it should be. It is entirely possible to have a normal lipid panel, a normal glucose, a normal TSH, and still be carrying an atherogenic particle burden, early insulin resistance, and a thyroid that is functionally underperforming for you.
Why particle count beats cholesterol
Cardiovascular risk is the clearest example of a marker most panels get wrong by omission. LDL cholesterol measures how much cholesterol your LDL particles are carrying. ApoB counts the particles themselves — one ApoB molecule per atherogenic particle — and it is the particles that lodge in the arterial wall. The two usually move together, which is why the difference took decades to demonstrate. When they diverge, which happens routinely in people with high triglycerides, insulin resistance, or metabolic syndrome, ApoB is the marker that tracks events. This is not a fringe position: European guidelines have recognised ApoB as the more accurate risk marker since 2019, and the evidence has continued to accumulate.
The markers that change decisions
A useful panel is not simply a longer panel. The markers worth adding are the ones that alter what you do next. Fasting insulin, read alongside glucose, exposes insulin resistance years before HbA1c drifts. High-sensitivity CRP quantifies the low-grade inflammation that connects visceral fat, poor sleep and cardiovascular risk. Lipoprotein(a) is largely genetic, needs measuring roughly once in a lifetime, and shifts prevention strategy substantially when elevated. A full thyroid picture — free T3 and free T4, not TSH alone — explains a great deal of unresolved fatigue. Ferritin and iron studies matter enormously in menstruating women whose haemoglobin is still normal. Vitamin D, B12 and magnesium are worth knowing because they are correctable.
Trends beat snapshots
One result is a data point. Health is a trajectory. Fasting glucose creeping from 84 to 96 over four years is a meaningful signal even though every value is normal; the same 96 in isolation tells you almost nothing. This is the single largest advantage of a practice that retests deliberately rather than annually by habit. It is also why we read labs alongside the rest of your life — training load, alcohol, travel, sleep, a new medication, a stressful quarter. A ferritin drop in someone who has just started marathon training means something different from the same drop in someone who has not.
What testing cannot do
Honesty here matters more than enthusiasm. Broad panels generate incidental findings, and some of those lead to follow-up testing that finds nothing while causing real anxiety. Some commercially popular tests have weak evidence behind them and we do not order them by default. Biological age calculators are interesting and not yet clinically actionable. Testing also cannot substitute for the interventions that actually move outcomes: sleep, resistance training, protein intake, alcohol reduction, and treatment of established disease. If a clinic sells you a panel and hands back a PDF, you have bought data, not care.
Preparation, timing and cost
Most panels require a 10 to 12 hour fast; our team confirms instructions when your draw is scheduled. Avoid intense exercise in the 24 hours before a draw, since it transiently raises inflammatory markers and creatine kinase. Time hormone panels to your cycle where relevant. Results typically return within one to two weeks and are reviewed with your physician in a dedicated visit, not sent by email. Organic Well does not participate with insurance plans; laboratory fees are disclosed in advance, and we provide superbills you can submit for potential out-of-network reimbursement.
From data to a plan
A review visit should end with three things: which markers matter for you, in what order, and what specifically changes this month. That might be a lipid-lowering decision driven by ApoB and Lp(a), a nutrition and training plan aimed at fasting insulin, a thyroid or iron correction, or a referral. It should also include a retest date, because the follow-up panel is what tells us whether the plan worked. Data without a decision is expensive reassurance.
What the research says
We cite the studies directly, including where the evidence is thin. Every link goes to the primary source.
ApoB outperformed LDL-C in 9 of 9 studies whereas LDL P was superior to LDL-C in 2 of 3 comparisons.
Sehayek S, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. Journal of Clinical Lipidology, 2025.
A systematic review of 15 discordance studies covering 593,354 participants. The authors conclude that neither LDL-C nor non-HDL-C is an adequate clinical surrogate for ApoB.
ApoB may be a superior biomarker for assessing long-term ASCVD risk, indicating that apoB-containing lipoprotein particle number, rather than cholesterol content, is a more robust predictor.
ATTICA study (2002–2022), European Journal of Clinical Investigation, 2025.
Twenty years of follow-up. Adding ApoB explained part of the residual risk left unexplained by LDL-C, non-HDL-C and Lp(a) alone.
Discordance typically occurs in patients with elevated triglycerides, small dense LDL particles, or metabolic syndrome features, where ApoB remains elevated despite apparently controlled LDL-C levels.
Journal of Clinical Lipidology, 2025.
The clinical picture in which a standard panel is most likely to reassure you wrongly — and precisely the metabolic profile we see most often in Miami.
Frequently asked questions
How is this different from my annual bloodwork?+
Panels are broader and interpreted for optimisation rather than only disease screening — we look at trends and optimal ranges, not just whether a value falls inside a population reference range.
Do I need to fast?+
Most panels require a 10 to 12 hour fast. Our team confirms preparation instructions when your draw is scheduled, including whether to hold supplements.
When do I get results?+
Most results return within one to two weeks and are reviewed with your physician in a dedicated visit.
Is ApoB available at standard labs?+
Yes. It is inexpensive, standardised and widely available. It is simply not ordered by default in most practices.
How often should Lp(a) be measured?+
Once is usually enough. It is largely genetically determined and does not vary much with lifestyle, but it meaningfully changes prevention strategy when elevated.
Will insurance cover advanced panels?+
Organic Well does not participate with insurance plans. Laboratory fees are disclosed in advance and superbills are provided for potential out-of-network reimbursement.
Can I bring labs from another physician?+
Please do. Prior results are genuinely valuable because they give us a trend line from the first visit rather than the third.
How soon should I retest?+
Most interventions are reassessed at 8 to 12 weeks. Structural markers such as Lp(a) do not need repeating.
When your health works better, everything does.
Tell us about your goals, your challenges, and what matters most to you — we'll take it from there.
Let's talk